Tenax Therapeutics, Inc. (TENX)
1.98
+0.13
(+7.03%)
USD |
NASDAQ |
Sep 03, 10:18
Tenax Therapeutics Research and Development Expense (Annual) : 32.67M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 32.67M |
| December 31, 2024 | 12.71M |
| December 31, 2023 | 3.229M |
| December 31, 2022 | 5.377M |
| December 31, 2021 | 25.15M |
| December 31, 2020 | 4.561M |
| December 31, 2019 | 3.471M |
| December 31, 2018 | 1.238M |
| December 31, 2017 | 3.524M |
| December 31, 2016 | 13.13M |
| April 30, 2015 | 6.627M |
| April 30, 2014 | 2.956M |
| April 30, 2013 | 2.413M |
| Date | Value |
|---|---|
| April 30, 2012 | 2.463M |
| April 30, 2011 | 2.682M |
| April 30, 2010 | 2.918M |
| April 30, 2009 | 1.599M |
| April 30, 2008 | 0.94M |
| April 30, 2007 | 0.7526M |
| April 30, 2006 | |
| April 30, 2005 | 1.277M |
| April 30, 2004 | 1.276M |
| April 30, 2003 | 1.433M |
| April 30, 2002 | 1.313M |
| April 30, 2001 | 0.7823M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 3.286M |
| Century Therapeutics, Inc. | 82.57M |
| Absci Corp. | 80.72M |
| Celularity, Inc. | 9.222M |